VAR - Varian Medical Systems, Inc.
130.47 0.00 (0.00%)
After hours: 4:17PM EDT
| Previous Close | 130.78 |
| Open | 130.06 |
| Bid | 129.01 x 800 |
| Ask | 130.52 x 1100 |
| Day's Range | 129.98 - 133.41 |
| 52 Week Range | 101.42 - 142.50 |
| Volume | 711,190 |
| Avg. Volume | 617,737 |
| Market Cap | 11.844B |
| Beta (3Y Monthly) | 0.96 |
| PE Ratio (TTM) | 33.08 |
| EPS (TTM) | 3.94 |
| Earnings Date | Apr 24, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 1998-12-02 |
| 1y Target Est | 148.71 |
- Zacks•10 hours ago
Edwards Lifesciences Takes Over CAS Medical Systems for $100M
This CASMED acquisition is expected to strengthen Edwards Lifesciences' (EW) critical care portfolio and expand its footprint in the smart monitoring technology market.
- Zacks•4 days ago
Varian Medical (VAR) to Report Q2 Earnings: What's in Store?
Varian Medical (VAR) expects to gain significantly from APAC and EMEA regions in fiscal Q2.
- Zacks•4 days ago
Here's Why You Should Invest in Chemed (CHE) Stock Right Now
Chemed (CHE) is expected to benefit from the launch of its VITAS Healthcare Inpatient Hospice Unit.
- Zacks•5 days ago
Varian Medical Systems (VAR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Varian (VAR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•5 days ago
Medidata Launches Acorn Artificial Intelligence Company
Driven by Medidata's (MDSO) standardized clinical data storehouse, and operating on its pioneering platform, Acorn AI is set to become one of the premier AI companies in the field of life sciences.
- Zacks•6 days ago
Here's Why You Should Buy Masimo (MASI) Stock Right Now
Masimo (MASI) has been benefitting from developments like the FDA clearance of the Rad-67 Pulse CO-Oximeter.
- Zacks•6 days ago
Top Ranked Momentum Stocks to Buy for April 16th
Top Ranked Momentum Stocks to Buy for April 16th
- Zacks•6 days ago
Hologic's Diagnostics Grows Strong, Escalating Costs a Woe
To fortify its product portfolio, Hologic (HOLX) is working on innovations and product introductions. On this front, Cynosure's R&D pipeline stays robust.
- Simply Wall St.•6 days ago
Is Varian Medical Systems, Inc. (NYSE:VAR) A High Quality Stock To Own?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. We'll use ROE to examine Varian Medical Systems...
- Zacks•10 days ago
ResMed Launches AirFit P30i Nasal Pillows Mask in the US
ResMed (RMD) to expand its portfolio of sleep apnea devices on the back of AirFit P30i nasal pillows mask.
- Zacks•11 days ago
Here's Why Investors Should Retain Accuray (ARAY) Stock Now
Management at Accuray (ARAY) sees significant opportunities in China.
- Zacks•12 days ago
Here's Why You Should Buy Varian Medical (VAR) Stock Now
Varian Medical (VAR) announces the installation of cyclotron for its ProBeam proton therapy system at the Hefei Ion Medical Center in China.
- Zacks•13 days ago
Align Rides on Firm Global Footprint Despite Fierce Rivalry
Align's (ALGN) solid performance in the Europe, Middle East and Africa and Asia-Pacific geographies is appreciative.
- Zacks•13 days ago
Varian Medical's (VAR) ProBeam Installed in China's HIMC
Varian Medical (VAR) has seen some notable developments in its Proton Therapy business in recent times.
- PR Newswire•14 days ago
Varian Installs Cyclotron for ProBeam Proton Therapy System at Hefei Ion Medical Center in China
PALO ALTO, Calif. and HEFEI, China , April 8, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced the installation of the cyclotron for the Varian ProBeam ® proton therapy system at Hefei Ion Medical ...
- Insider Monkey•17 days ago
Hedge Funds Have Never Been This Bullish On Varian Medical Systems (VAR)
Is Varian Medical Systems, Inc. (NYSE:VAR) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a […]
- Zacks•17 days ago
Here's Why You Should Hold Becton, Dickinson Stock for Now
Becton, Dickinson (BDX) announces the FDA premarket approval for Venovo venous stent device.
- Zacks•17 days ago
ABIOMED Impella Data Show Significant Rise in Survival Rates
ABIOMED (ABMD) plans to expand products like Impella CP, Impella Connect, Impella 5.5 and Impella RP.
- Zacks•18 days ago
Varian Medical Opens Office in South Africa, Expands in EMEA
Varian Medical (VAR) sees a slew of developments in the EMEA region of late.
- PR Newswire•19 days ago
Varian Opens Office in South Africa to Support Regional Growth
PALO ALTO, Calif. , April 4, 2019 /PRNewswire/ -- At a grand opening ceremony held March 8th , the Varian office in Hertford Office Park, Midrand, Johannesburg, South Africa was officially inaugurated. ...
- Zacks•19 days ago
Integra's Product Launch a Growth Catalyst, Rivalry Rife
Product launches and a sales force performance upgrade are likely to boost rapid organic growth for Integra LifeSciences (IART) in the second half of 2019.
- Zacks•19 days ago
Varian Announces Halcyon's First Successful Case in Malaysia
Varian's (VAR) Halcyon is much superior to traditional technologies, thanks to the speed of treatment and improved quality of patient care it offers.
- PR Newswire•19 days ago
Varian Discloses First Preclinical Results of Potential Major Breakthrough in Cancer Treatment
PALO ALTO, Calif., April 3, 2019 /PRNewswire/ -- At the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, GA, Varian (VAR), in partnership with the University of Maryland School of Medicine's Department of Radiation Oncology and the Maryland Proton Treatment Center, presented publicly the first pre-clinical results of its research on ultra-high dose rate cancer treatments with protons. Known as Flash therapy, it is a non-invasive therapy for cancer delivering high doses of radiation in ultra-high-speeds (less than 1 second) and represents the potential for a major breakthrough in the treatment of cancer. The preclinical Flash therapy results presented at AACR showed reduced toxicity in healthy tissues and organs.
- GuruFocus.com•20 days ago
Varian Medical Systems Inc (VAR) President and CEO Dow R Wilson Sold $6.4 million of Shares
President and CEO of Varian Medical Systems Inc (NYSE:VAR) Dow R Wilson sold 45,050 shares of VAR on 03/29/2019 at an average price of $141.58 a share.
- Markit•20 days ago
See what the IHS Markit Score report has to say about Varian Medical Systems Inc.
Varian Medical Systems Inc NYSE:VARView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for VAR with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting VAR. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding VAR are favorable, with net inflows of $11.77 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
